Boulder, CO – According to filings with the U.S. Securities and Exchange Commission, Inscripta is raising $8,060,048.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Sri Kosaraju played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Inscripta

Making the MAD7 CRISPR nuclease free for research purposes may not be typical in this industry, but it’s typical for us. Our primary purpose is to empower scientists whose gene editing research is stifled by current technical and licensing limitations. We want you to make bigger discoveries, faster and at unprecedented scale, experiencing those bold breakthroughs that the Onyx platform will provide. We live up to our press by ?’walking the walk’ every day, bringing you revolutionary tools that serve the greater good. Because Inscripta is more than a company, it’s our calling.

To learn more about Inscripta, visit http://www.inscripta.com/

Contact:
Sri Kosaraju, Chief Executive Officer
720-759-4088
https://www.linkedin.com/in/sri-kosaraju-a0a8051aa/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved